Novel CAR-T Therapy for Glioblastoma
Tech ID: 33620 / UC Case 2018-141-0
Technology Description
There are currently no effective therapies for glioblastoma (GBM). Median survival is < 18months. Previous studies targeting GBM with anti-EGFRviii CAR produced a consistent recurrence. EphA2 and IL13Ra2 are widely expressed in GBM but have imperfect specificity. Our inventors have thus developed a CAR-T cell therapy that recognizes EGFRviii+ cells and then kills in the presence of EPHA2 or IL13R⍺2. This multi-antigen targeting strategy uses the synNotch "prime and kill" circuit.
Stage of Development
EGFRviii is IND approved with recruitment for phase 1 dose escalation in GBM patients ongoing.
Related Materials
- SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma - 04/28/2021
Patent Status
| Country | Type | Number | Dated | Case |
| China | Published Application | 115151268 | 10/04/2022 | 2020-184 |
| European Patent Office | Published Application | 4054596 | 09/14/2022 | 2020-145 |
| European Patent Office | Published Application | 3773632 | 02/17/2021 | 2018-141 |
| European Patent Office | Published Application | 3773623 | 02/17/2021 | 2018-142 |
| European Patent Office | Published Application | 3,773,633 | 02/17/2021 | 2018-143 |
| United States Of America | Published Application | 20210023138 | 01/28/2021 | 2018-141 |
| United States Of America | Published Application | 20210023136 | 01/28/2021 | 2018-142 |
| United States Of America | Published Application | 20210023139 | 01/28/2021 | 2018-143 |
| Australia | Published Application | 2018-141 | ||
| Canada | Published Application | 2018-141 | ||
| Australia | Published Application | 2018-142 | ||
| Canada | Published Application | 2018-142 | ||
| Australia | Published Application | 2018-143 | ||
| Canada | Published Application | 2018-143 | ||
Additional Patents Pending
Contact
- Gemma E. Rooney
- Gemma.Rooney@ucsf.edu
- tel: View Phone Number.
Other Information
Keywords
CAR-T, Glioblastoma, Rare disease, SynNotch, Multi-Antigen, EGFRviii, EPHA2, IL13R?2